- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Why Is Sight Sciences Stock Gaining Thursday? | 1 | Benzinga.com | ||
| 01.10. | Sight Sciences, Inc.: Sight Sciences to Debut the OMNI Ultra Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 19.08. | Sight Sciences Announces FDA Label Expansion For TearCare Dry Eye Therapy | 1 | RTTNews | ||
| 19.08. | Sight Sciences, Inc.: TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease | 480 | GlobeNewswire (Europe) | MENLO PARK, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative interventional technologies... ► Artikel lesen | |
| 10.08. | Sight Sciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.08. | Sight Sciences outlines 2026 revenue of $88M-$92M while lowering adjusted operating expense outlook to $92M-$94M | 2 | Seeking Alpha | ||
| SIGHT SCIENCES Aktie jetzt für 0€ handeln | |||||
| 06.08. | Sight Sciences GAAP EPS of -$0.08 beats by $0.06, revenue of $23.4M beats by $1.71M | 1 | Seeking Alpha | ||
| 05.08. | Earnings Call: Sight Sciences hebt Ausblick für 2026 an, Aktie fällt trotz Q2-Wachstum | - | Investing.com Deutsch | ||
| 05.08. | Sight Sciences: Aetna erweitert Kostenerstattung für Glaukom-Systeme | 8 | Investing.com Deutsch | ||
| 05.08. | Sight Sciences wins FDA clearance for Omni Surgical System | 2 | MassDevice | ||
| 05.08. | FDA clears Sight Sciences' OMNI Ultra glaucoma device | 1 | Investing.com | ||
| 04.08. | Sight Sciences, Inc.: Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System | 169 | GlobeNewswire (Europe) | MENLO PARK, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative interventional technologies... ► Artikel lesen | |
| 22.07. | Sight Sciences, Inc.: Sight Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026 | 1 | GlobeNewswire (USA) | ||
| 05.06. | Sight Sciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.05. | Sight Sciences signals $83M-$89M 2026 revenue outlook while targeting $6M-$8M dry eye sales | 1 | Seeking Alpha | ||
| 06.05. | Sight Sciences, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 23.04. | Sight Sciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.04. | Sight Sciences, Inc.: Sight Sciences Announces the Release of its Sustainability Report | 3 | GlobeNewswire (USA) | ||
| 04.03. | Sight Sciences, Inc.: Sight Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Initiates Full Year 2026 Financial Guidance | 210 | GlobeNewswire (Europe) | MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing... ► Artikel lesen | |
| 13.01. | Sight Sciences, Inc.: Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Highlights | 367 | GlobeNewswire (Europe) | MENLO PARK, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 4,995 | -1,09 % | Teladoc Health, Inc.: Teladoc Health to Announce Third Quarter 2026 Financial Results | ||
| SERNOVA BIOTHERAPEUTICS | 0,075 | +5,93 % | Sernova Biotherapeutics Inc: Sernova partner Seraxis names new chief medical head | ||
| CERENOME | 1,440 | -8,40 % | Cerenome, Inc.: Cerenome Launches CNSide CSF Molecular Profile Tests | HOUSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), today announced the commercial launch... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 2,440 | -6,15 % | Atossa Therapeutics: Stammaktien handeln ab sofort gekoppelt mit Contingent Value Rights | ||
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -5- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS75973T2006 RENALYTIX... ► Artikel lesen | |
| TANDEM DIABETES | 15,100 | +4,14 % | Tandem Diabetes Care Q2 2026 Earnings Call Transcript | ||
| CO-DIAGNOSTICS | 0,666 | 0,00 % | Co-Diagnostics, Inc. - 8-K, Current Report | ||
| QUIDELORTHO | 12,715 | +10,66 % | QuidelOrtho Reports Q2 2026 Results: Full Earnings Call Transcript | ||
| VERU | 2,300 | 0,00 % | Oppenheimer reiterates Veru stock rating ahead of obesity trial data | ||
| LIFEWARD | 5,930 | -1,66 % | 6,4 Millionen US-Dollar pro Patient: Warum Medtronic, Lifeward und NurExone an drei Stufen der Rückenmarksversorgung ansetzen | ||
| CLOVER HEALTH INVESTMENTS | 3,890 | -2,26 % | Why Is Clover Health (CLOV) Stock Soaring Today | ||
| SENSEONICS | 7,050 | +2,17 % | Senseonics Holdings Q2 2026 Earnings Call: Complete Transcript | ||
| NANO-X IMAGING | 0,414 | 0,00 % | Nanox meldet vorläufigen Q3-Umsatz von bis zu $4,4 Millionen | ||
| TEMPEST THERAPEUTICS | 0,600 | 0,00 % | Tempest Therapeutics: Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise | ||
| IMUNON | 0,785 | -7,10 % | Imunon, Inc.: IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer | Enrollment momentum exceeding expectations is based on highly promising survival (OS) data and well tolerated safety profile demonstrated in the Company's large, randomized Phase II study, OVATION... ► Artikel lesen |
Das Unternehmen SIGHT SCIENCES INC kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 8,270 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SIGHT SCIENCES INC finden Sie auf Wallstreet Online.